|Articles|September 13, 2018
Global Clinical Trial Partners Selects AG Mednet PR
Advertisement
GLASGOW and BOSTON – September 6, 2018 – Global Clinical Trial Partners (GCTP) has chosen AG Mednet’s Judi as its sole technology provider to deliver its enhanced, rigorous, single-vendor endpoint adjudication services to its clients. GCTP’s independent adjudication offering focuses on management of clinical event committees (CECs). The company provides endpoint adjudication for clinical trials as well as bespoke clinical trial consultancy, with a team of world-renowned clinical trial experts and academics in concert with pharmaceutical industry experts.
With Judi, GCTP will deliver a robust end-to-end, technologically advanced adjudication solution for clients by implementing their expertise in a concise, reproducible and efficient set of workflow methodologies that have been tried and tested in dozens of projects over more than 25 years.
GCTP works collaboratively with clients to determine an approach that best suits their unique needs and handles development of the endpoint process from start to finish. The company manages all aspects of the CEC process from small, single-center to large multinational, multi-center studies. Specific to adjudication, through Judi, GCTP provides:
- Endpoint data capture via eCRF
- Endpoint process management
- Integration of the CEC process within trial frameworks
- Overall electronic adjudication system development
- Adjudication data packet assembly
According to Professor Mark Petrie of GCTP, “AG Mednet’s Judi software is the perfect fit for our bespoke adjudication solutions. The flexibility of their software allows us to easily implement workflow that not only enhances endpoint data quality, but also makes the end-user experience positively enjoyable.”
“Global Clinical Trial Partners is unique in a number of important ways. Not only have they published pioneering peer-reviewed articles in the most important journals in the world, but they have brought their clinical expertise to a level where sponsors can benefit from their experience. Their customer-centric approach to endpoint adjudication represents a breath of fresh air in the industry. Using Judi as the technology backbone to power their processes is a perfect solution to what is already among the most comprehensive, efficient and accurate approaches to adjudication,” said Abraham Gutman, president and CEO, AG Mednet.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- NIMBLE Trial Reveals New Insights on Complement Inhibition in gMG
September 15th 2025
- Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Capvaxive Demonstrates Robust Immune Responses in Children, Adolescents at Increased Risk of Pneumococcal Disease
2
NIMBLE Trial Reveals New Insights on Complement Inhibition in gMG
3
ACT Brief Weekly Recap: How AI, eClinical Innovation, and Policy Shifts Are Reshaping Clinical Research
4